ChristopherHanyoungLieuMD

Associate Professor, University of Colorado School of Medicine

Overview of Dr. Lieu

Dr. Christopher Lieu is an oncologist in Aurora, CO and is affiliated with University of Colorado Hospital. He received his medical degree from Wake Forest School of Medicine of Wake Forest Baptist Medical Center and has been in practice 13 years. He is one of 121 doctors at University of Colorado Hospital who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
12605 E 16th Ave
Aurora, CO 80045
Book by Phone+1(231) 354-3835

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
University of ColoradoResidency, Internal Medicine, 2004 - 2007
Wake Forest School of Medicine of Wake Forest Baptist Medical CenterClass of 2004

Certifications & Licensure

TX State Medical License 2008 - 2026
CO State Medical License 2007 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment Start of enrollment: 2012 Jan 01
Completed
Phase 1
Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer Start of enrollment: 2013 Feb 12
Terminated
Phase 1, Phase 2
Metabiomics Colon Cancer Clinical Research Study Start of enrollment: 2019 Mar 01
Unknown status
Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer Start of enrollment: 2014 Aug 29
COMPLETED
PHASE1
Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies Start of enrollment: 2015 Dec 01
Terminated
Phase 2
Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas Start of enrollment: 2018 Oct 10
RECRUITING
PHASE1
Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors Start of enrollment: 2021 Apr 11
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Roles: Contact
FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer Start of enrollment: 2022 Mar 21
RECRUITING
PHASE2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

1 citations
Risk Without Reward: Differing Patterns of Chemotherapy Use Do Not Improve Outcomes in Stage II Early-Onset Colon Cancer.
Jacob B Leary, Junxiao Hu, Alexis Leal, S Lindsey Davis, Sunnie Kim
JCO Oncology Practice. 2025-03-01
Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group.
Lakshmi Rajdev, Gentry G King, Christopher H Lieu, Stacey A Cohen, Shubham Pant
JCO Precision Oncology. 2025-03-01
Genomic Landscapes of Early-Onset Versus Average-Onset Colorectal Cancer Populations.
Michael H Storandt, Qian Shi, Cathy Eng, Christopher Lieu, Thomas George
Cancers. 2025-02-28

Journal Articles

Association of Cancer Immunotherapy with Acute Macular Neuroretinopathy and Diffuse Retinal Venulitis
Sharon Solomon, Christopher H Lieu, Ashvini Reddy, Leisha A Emens, S Lindsey Davis, Lingmin He, JAMA

Lectures

Addressing Survivorship in Cancer Care
ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019

Press Mentions

Overcoming Colorectal Cancer Screening Barriers: 4 Leaders Weigh InMarch 24th, 2025
CU Cancer Center’s ‘FIT for Life’ Colorectal Cancer Screening Program Goes OnlineMarch 14th, 2025
The University of Colorado Cancer Center and Flatiron Health Announce Collaboration to Drive More Efficient Clinical TrialsMarch 5th, 2025
Join now to see all